These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36713520)

  • 1. The evolving role of radiation in pancreatic cancer.
    Malla M; Fekrmandi F; Malik N; Hatoum H; George S; Goldberg RM; Mukherjee S
    Front Oncol; 2022; 12():1060885. PubMed ID: 36713520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
    Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
    Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation therapy in borderline resectable pancreatic cancer: A review.
    Turner KM; Delman AM; Kharofa JR; Smith MT; Choe KA; Olowokure O; Wilson GC; Patel SH; Sohal D; Ahmad SA
    Surgery; 2022 Jul; 172(1):284-290. PubMed ID: 35034793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updates on the use of neoadjuvant therapy in borderline resectable pancreatic cancer.
    Chandhok NS; Saif MW
    JOP; 2014 Mar; 15(2):91-4. PubMed ID: 24618425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
    Shaib WL; Ip A; Cardona K; Alese OB; Maithel SK; Kooby D; Landry J; El-Rayes BF
    Oncologist; 2016 Feb; 21(2):178-87. PubMed ID: 26834159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation.
    Amodeo S; Masi A; Melis M; Ryan T; Hochster HS; Cohen DJ; Chandra A; Pachter HL; Newman E
    J Gastrointest Oncol; 2018 Oct; 9(5):922-935. PubMed ID: 30505595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy.
    Blair AB; Rosati LM; Rezaee N; Gemenetzis G; Zheng L; Hruban RH; Cameron JL; Weiss MJ; Wolfgang CL; Herman JM; He J
    Surgery; 2018 May; 163(5):1090-1096. PubMed ID: 29395234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy for Resectable and Borderline Resectable Pancreas Cancer: When and Why?
    Maxwell JE; Katz MHG
    J Gastrointest Surg; 2021 Mar; 25(3):843-848. PubMed ID: 33205307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of neoadjuvant therapy in the management of pancreatic cancer: is the era of biomarker-directed therapy here?
    Tsvetkova EV; Asmis TR
    Curr Oncol; 2014 Aug; 21(4):e650-7. PubMed ID: 25089113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Sulciner ML; Ashley SW; Molina G
    J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of borderline resectable pancreatic cancer.
    Mahipal A; Frakes J; Hoffe S; Kim R
    World J Gastrointest Oncol; 2015 Oct; 7(10):241-9. PubMed ID: 26483878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary Management of Localized Resectable Pancreatic Cancer.
    Kommalapati A; Tella SH; Goyal G; Ma WW; Mahipal A
    Cancers (Basel); 2018 Jan; 10(1):. PubMed ID: 29361690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Localized Pancreatic Cancer: Multidisciplinary Management.
    Coveler AL; Herman JM; Simeone DM; Chiorean EG
    Am Soc Clin Oncol Educ Book; 2016; 35():e217-26. PubMed ID: 27249726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis.
    Brown ZJ; Heh V; Labiner HE; Brock GN; Ejaz A; Dillhoff M; Tsung A; Pawlik TM; Cloyd JM
    Br J Surg; 2022 Dec; 110(1):34-42. PubMed ID: 36346716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
    Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
    BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma.
    Iyengar S; Nevala-Plagemann C; Garrido-Laguna I
    Ther Adv Med Oncol; 2021; 13():17588359211045861. PubMed ID: 34552668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review and current state of radiation therapy for locally advanced pancreatic adenocarcinoma.
    Blakaj A; Stein SM; Khan SA; Johung KL
    J Gastrointest Oncol; 2018 Dec; 9(6):1027-1036. PubMed ID: 30603121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of chemoradiotherapy in the adjuvant and neoadjuvant settings for resectable pancreatic cancer.
    Sen N; Falk S; Abrams RA
    Clin Oncol (R Coll Radiol); 2014 Sep; 26(9):551-9. PubMed ID: 25024090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant radiotherapeutic strategies in pancreatic cancer.
    Roeder F
    World J Gastrointest Oncol; 2016 Feb; 8(2):186-97. PubMed ID: 26909133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary advanced unresectable pancreatic cancer.
    Wilkowski R; Wolf M; Heinemann V
    Recent Results Cancer Res; 2008; 177():79-93. PubMed ID: 18084950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.